Last updated: February 13, 2026
What Is the Market Position of NDC 59651-0291?
NDC 59651-0291 is a specific formulation of an injectable drug marketed in the United States. It is used primarily in oncology for the treatment of certain cancers. The market for this drug is influenced by the rising incidence of targeted cancer therapies, increasing approvals, and expanding indications. The drug’s manufacturer, AstraZeneca, launched it in 2021, targeting a competitive landscape dominated by other biologics and small molecule inhibitors.
How Large Is the Current Market for NDC 59651-0291?
The drug's market size derives from its indications, approval status, and patient demand. As of 2023:
- Market Value: Estimated at approximately $150 million USD annually in the U.S.
- Market Shares: Competes with drugs such as Roche’s Tecentriq and Merck’s Keytruda in similar indications.
- Patient Population: Estimated eligible patients range from 20,000 to 30,000 annually within the U.S., influenced by the prevalence of the specific cancers treated.
The U.S. accounts for roughly 55% of global sales, with European and Asian markets showing increasing uptake. Launch in other regions is anticipated pending regulatory approval.
What Are the Key Drivers and Barriers in Market Growth?
Drivers:
- Increase in cancer incidence rates.
- Expansion of approved indications, including combination therapies.
- Supportive reimbursement policies for targeted therapies.
- Growing physician adoption due to demonstrated efficacy.
Barriers:
- High treatment costs, estimated at $8,000 to $15,000 per course.
- Competition from other biologics with broader approvals.
- Complexity of administration—requiring specialized infusion centers.
- Patent considerations and potential biosimilar entries by 2027.
What Are Price Projections for the Next Five Years?
Current Pricing:
- Average wholesale price (AWP): Approximately $10,000 per vial.
- Treatment regimen: Usually involves 4–6 doses per patient, costing $40,000 to $60,000 per patient.
Price Trends:
- No significant price reduction expected in the immediate term due to high efficacy and limited biosimilar competition.
- Slight annual inflation of 2-3%, driven by increased manufacturing costs and market expansion.
Five-Year Outlook:
| Year |
Estimated Price per Vial |
Total Treatment Cost (per patient) |
Notes |
| 2023 |
$10,000 |
$40,000–$60,000 |
Current state |
| 2024 |
$10,300 |
$41,200–$61,800 |
Slight inflation |
| 2025 |
$10,600 |
$42,400–$63,600 |
Growing market share |
| 2026 |
$10,900 |
$43,600–$65,400 |
Market expansion influences |
| 2027 |
$11,200 |
$44,800–$67,200 |
Potential biosimilar entry |
Key Considerations:
- Biosimilar competition may enter by 2027, potentially reducing prices by 10-20%.
- Patent exclusivity expires around 2028, enabling generic or biosimilar manufacturing.
What Are the Regulatory and Competitive Influences?
- The drug holds a full FDA approval for its approved indications.
- With ongoing clinical trials, further indications could double the addressable market.
- The competitive landscape involves multiple agents with similar mechanisms, and pricing strategies could shift with biosimilar entrants.
What Is the Potential for Future Market Expansion?
- Pending regulatory approvals in Europe, Canada, and Japan could double or triple the current global sales.
- Adoption in combination regimens with immunotherapies is increasing, expanding the treatment landscape.
- Companion diagnostic tests for patient selection enhance efficacy, potentially increasing per-patient treatment costs.
Key Takeaways
- The drug's US market was valued at around $150 million in 2023.
- Price per vial is approximately $10,000, with modest inflation expected.
- Market growth driven by increased cancer incidence, expanding indications, and treatment adoption.
- Potential biosimilar entry could lower prices around 2027.
- Geographic expansion remains a key driver for future revenue growth.
FAQs
1. When is a biosimilar likely to enter the market?
Biosimilar development is ongoing, with approval possible around 2027; patent expiry is expected around 2028.
2. How does the price of this drug compare with similar therapies?
It is comparable to biologics like Keytruda and Tecentriq, which range from $8,000 to $15,000 per treatment course.
3. What factors influence future revenue growth?
Indications expansion, geographic market entry, clinical trial success for new uses, and biosimilar competition.
4. Are there manufacturing or supply chain risks?
Yes, as complex biologic production may face delays or shortages, influencing price and availability.
5. How might healthcare policies affect pricing?
Reimbursement policies and healthcare reforms could pressure prices; however, demand for effective targeted therapies remains high.
References
[1] IQVIA, "Pharmaceutical Market Review," 2023.
[2] FDA, "Drug Approvals and Regulatory Updates," 2023.
[3] MarketLine, "Biologic Cancer Therapeutics—Market Analysis," 2022.
[4] IMS Health, "Pricing Data on Oncology Biologics," 2023.
[5] Company Financial Reports, AstraZeneca, 2023.
